Ad is loading...
ALLO
Price
$2.27
Change
-$0.19 (-7.72%)
Updated
Nov 15 closing price
101 days until earnings call
SPRO
Price
$1.18
Change
-$0.07 (-5.60%)
Updated
Nov 15 closing price
116 days until earnings call
Ad is loading...

ALLO vs SPRO

Header iconALLO vs SPRO Comparison
Open Charts ALLO vs SPROBanner chart's image
Allogene Therapeutics
Price$2.27
Change-$0.19 (-7.72%)
Volume$3.09M
CapitalizationN/A
Spero Therapeutics
Price$1.18
Change-$0.07 (-5.60%)
Volume$465.37K
CapitalizationN/A
ALLO vs SPRO Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALLO vs. SPRO commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Sell and SPRO is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (ALLO: $2.27 vs. SPRO: $1.18)
Brand notoriety: ALLO and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 142% vs. SPRO: 182%
Market capitalization -- ALLO: $475.96M vs. SPRO: $63.78M
ALLO [@Biotechnology] is valued at $475.96M. SPRO’s [@Biotechnology] market capitalization is $63.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 4 bearish.
  • SPRO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than SPRO.

Price Growth

ALLO (@Biotechnology) experienced а -26.30% price change this week, while SPRO (@Biotechnology) price change was -10.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

SPRO is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($476M) has a higher market cap than SPRO($63.8M). SPRO YTD gains are higher at: -19.728 vs. ALLO (-29.283). SPRO has higher annual earnings (EBITDA): 19.6M vs. ALLO (-256.56M). ALLO has more cash in the bank: 445M vs. SPRO (63.5M). SPRO has less debt than ALLO: SPRO (4.94M) vs ALLO (87M). SPRO has higher revenues than ALLO: SPRO (105M) vs ALLO (65K).
ALLOSPROALLO / SPRO
Capitalization476M63.8M746%
EBITDA-256.56M19.6M-1,309%
Gain YTD-29.283-19.728148%
P/E RatioN/A3.47-
Revenue65K105M0%
Total Cash445M63.5M701%
Total Debt87M4.94M1,762%
FUNDAMENTALS RATINGS
ALLO vs SPRO: Fundamental Ratings
ALLO
SPRO
OUTLOOK RATING
1..100
655
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9538
PRICE GROWTH RATING
1..100
8061
P/E GROWTH RATING
1..100
10047
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (27) in the Pharmaceuticals Major industry is significantly better than the same rating for ALLO (97) in the Biotechnology industry. This means that SPRO’s stock grew significantly faster than ALLO’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ALLO (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to ALLO’s over the last 12 months.

SPRO's SMR Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALLO (95) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than ALLO’s over the last 12 months.

SPRO's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as ALLO (80) in the Biotechnology industry. This means that SPRO’s stock grew similarly to ALLO’s over the last 12 months.

SPRO's P/E Growth Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALLO (100) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOSPRO
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 7 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
87%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RWIIX14.34N/A
N/A
Redwood AlphaFactor Tactical Intl I
TRLCX23.69-0.06
-0.25%
Nuveen Large Cap Value Retire
HDVIX12.35-0.07
-0.56%
Hartford International Equity I
SRIAX14.15-0.08
-0.56%
Gabelli SRI A
CLSPX31.02-0.54
-1.71%
Columbia Select Mid Cap Gro Fd I

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-7.72%
FATE - ALLO
58%
Loosely correlated
-2.88%
NTLA - ALLO
56%
Loosely correlated
-7.61%
BEAM - ALLO
55%
Loosely correlated
-8.59%
CRSP - ALLO
54%
Loosely correlated
+0.85%
CRBU - ALLO
54%
Loosely correlated
-4.78%
More

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with LXRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then LXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-5.60%
LXRX - SPRO
39%
Loosely correlated
-8.00%
ABOS - SPRO
34%
Loosely correlated
-8.05%
XNCR - SPRO
33%
Loosely correlated
-1.83%
ALLO - SPRO
32%
Poorly correlated
-7.72%
TECH - SPRO
32%
Poorly correlated
-6.85%
More